ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03323151
Recruitment Status : Recruiting
First Posted : October 26, 2017
Last Update Posted : November 2, 2018
Sponsor:
Collaborator:
Takeda
Information provided by (Responsible Party):
PrECOG, LLC.

Brief Summary:

Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib.

Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for patients with mantle cell lymphoma who have received at least one prior therapy.

Ixazomib is in a class of medications called proteasome inhibitors. Cancer cells depend on proteasome to provide this protein metabolism (turnover) function to regulate their growth and survival. Ixazomib disrupts a cancer cells' ability to survive by blocking the proteasome and disrupting protein metabolism. This may help to slow down the growth of cancer or may cause cancer cells to die.

The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory MCL and to examine the side effects associated with ixazomib in combination with ibrutinib.


Condition or disease Intervention/treatment Phase
Mantle-Cell Lymphoma Drug: Ixazomib Drug: Ibrutinib Phase 1 Phase 2

Detailed Description:

MCL is a rare subtype of non-Hodgkin lymphoma that is considered incurable with conventional therapy. For relapsed patients, Ibrutinib, lenalidomide, and bortezomib are all approved by the FDA but are not curative. Novel approaches are required to improve outcomes for patients with relapsed/refractory MCL.

This is an open-label study that will be done in 2 phases. Phase I will test different doses of ixazomib and ibrutinib to determine the maximum safe and tolerated dose. In Phase I, patients who have already received ibrutinib, may participate if they meet certain criteria (i.e., have not received ibrutinib for at least 3 months).

Phase II will find out the effects, good and/or bad, of ixazomib in combination with ibrutinib. In Phase II, patients will be separated into 2 groups, patients who have never received ibrutinib and patients who have received ibrutinib. This study is designed to examine the effectiveness of this drug in treating patients with MCL.

Patients will be treated until progression or unacceptable toxicity.

Tumor assessments will be performed approximately every 3 months for the first year of treatment, then every 6 months until progression.

Mandatory bone marrow and tumor tissue samples (i.e., obtained during a previous procedure or biopsy) are required at baseline. Mandatory research blood samples will also be collected.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Phase I: Standard 3+3 design with the primary objective of determining the maximum tolerate dose (MTD)/recommended phase 2 dose (RP2D) of this combination in MCL. Both ibrutinib-pretreated and ibrutinib-naïve patients will be enrolled.

Phase II: MTD/RP2D. Patients will be enrolled to two cohorts, based on prior ibrutinib treatment: ibrutinib-pretreated and ibrutinib-naïve.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Actual Study Start Date : August 13, 2018
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Phase I: Ixazomib & Ibrutinib
Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
Drug: Ixazomib
Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ixazomib 3 mg) or escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities.
Other Name: Ninlaro

Drug: Ibrutinib
Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
Other Name: Imbruvica

Experimental: Phase II: Ixazomib & Ibrutinib-Naive
Patients who are Ibrutinib-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
Drug: Ixazomib
Ixazomib by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
Other Name: Ninlaro

Drug: Ibrutinib
Ibrutinib by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
Other Name: Imbruvica

Experimental: Phase II: Ixazomib & Ibrutinib Pre-Treated
Patients previously treated with Ibrutinib will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
Drug: Ixazomib
Ixazomib by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
Other Name: Ninlaro

Drug: Ibrutinib
Ibrutinib by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
Other Name: Imbruvica




Primary Outcome Measures :
  1. Phase I: Maximum Tolerated Dose (MTD) [ Time Frame: 15 months ]
    MTD of ixazomib in mg in combination with ibrutinib in mg

  2. Phase II: Complete Response Rate [ Time Frame: 60 months ]
    CR rate will be the defined as the percentage of patients achieving CR as confirmed by bone marrow biopsy within the first 12 months of initiating treatment.


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Phase I: 15 months; Phase II: 60 months ]
    Number of patients with abnormal laboratory values and/or adverse events related to treatment

  2. Overall Response Rate (ORR) [ Time Frame: Phase I: 15 months; Phase II: 60 months ]
    ORR assessed in accordance with Lugano classification

  3. Progression-Free Survival (PFS) [ Time Frame: Phase I: 15 months; Phase II: 60 months ]
    PFS assessed in accordance with Lugano classification

  4. Overall Survival (OS) [ Time Frame: Phase I: 15 months; Phase II: 60 months ]
    OS assessed in accordance with Lugano classification



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Relapsed or refractory, pathologically proven mantle cell lymphoma. Must have a current or prior tissue sample that is IHC positive for cyclin D 1 or that is positive by FISH or cytogenetics for t(11;14).
  • Must have been refractory to and/or relapsed/progressed after at least 1 prior therapy.
  • Prior autologous or allogeneic transplant are allowed. Patients may not have active grade II-IV acute graft-versus-host disease (GVHD) or moderate/severe chronic GVHD by NIH criteria and may not require immunosuppressive medications and/or corticosteroids for the management of acute or chronic GVHD.
  • Phase I: Prior proteasome inhibitor and/or Bruton's tyrosine kinase (BTK) inhibitors are allowed but patients may not have been exposed to the combination of proteasome inhibitor and BTK inhibitor. Patients who have progressed on ibrutinib that are felt to be at high risk for rapid progression on this study shall not be eligible for the phase I portion of the study. NOTE: Ibrutinib pre-treated patients must meet all eligibility criteria AND must have discontinued prior ibrutinib at least 3 months prior to starting study therapy.
  • Phase II: Prior proteasome inhibitor and/or Bruton's tyrosine kinase inhibitors are allowed but patients may not have been exposed to the combination of proteasome inhibitor and BTK inhibitor. NOTE: Patients must have tolerated prior ibrutinib (i.e., not discontinued therapy due to toxicity).
  • Age ≥ 18 years.
  • Eastern Oncology Oncology Group (ECOG) performance status of 0-2.
  • Ability to understand and willingness to sign Institutional Review Board (IRB)-approved informed consent.
  • Willing to provide archived tumor tissue and blood samples for research.
  • Adequate organ function as measured by the following criteria

    • Absolute Neutrophil Count (ANC) ≥ 750/mm³
    • Platelets ˃50,000/mm³
    • Serum Creatinine ≤ 2x Upper Limit Normal (ULN)
    • ALT and AST ≤ 3x ULN
    • Total Bilirubin ≤ 1.5x ULN
  • Patients must not have received systemic treatment for MCL for at least 14 days prior to enrollment, except for steroids which may be used to manage acute symptoms related to disease up to 48 hours prior to starting study therapy. Radiation therapy must be concluded at least 14 days prior to enrollment.
  • Women must not be pregnant or breastfeeding since we do not know the effects of ixazomib and ibrutinib on the fetus or breastfeeding child. All sexually active females of childbearing potential must have a blood test to rule out pregnancy within 2 weeks prior to registration.
  • Sexually active women of child-bearing potential with a non-sterilized male partner and sexually active men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation, and for 3 months following last dose of study drugs.
  • Patients must have resolved all prior non-hematologic toxicities assessed as related to prior therapy to ≤ grade 1.
  • Patients must have measurable disease (i.e., ≥ 1.5 cm in largest diameter) by conventional imaging modalities. Patients with spleen or extranodal involvement as the only measurable site of disease must have a discrete splenic lesion ≥ 1.5 cm in largest diameter.
  • Patients may not have current/active Central Nervous System (CNS) involvement with mantle cell lymphoma (patients with prior CNS involvement are eligible as long as they have had no evidence of active CNS disease for at least 6 months).
  • Patients may not have another malignancy that could interfere with the evaluation of safety or efficacy of this combination. Patients with a prior malignancy will be allowed without study chair approval in the following circumstances:

    • Not currently active and diagnosed at least 3 years prior to the date of enrollment.
    • Non-invasive diseases such as low risk cervical cancer or any cancer in situ
    • Localized disease in which chemotherapy would not be indicated (such as Stage I colon, lung, prostate or breast cancer). Patients with other malignancies not meeting these criteria must be discussed with PrECOG prior to enrollment.
  • Patients requiring long-term anticoagulation must be managed on an anticoagulant besides warfarin. Patients who require warfarin are not eligible.
  • Patients with a clinically significant bleeding episode as judged by the investigator within 3 months of registration are not eligible, except patients who suffer bleeding due to trauma.
  • Patients may not have had major surgery within 14 days, or minor surgery within 3 days, before registration.
  • Patients may not have any active infection requiring oral or intravenous antimicrobial therapy at the time of therapy initiation. Patients with a recent self-limited infection that has clinically resolved may complete a prescribed course of antimicrobial therapy after study initiation as long as they are asymptomatic with no clinical evidence of infection for at least 7 days prior to treatment. Patients with a recent serious (grade ≥ 3) infection requiring hospitalization must have completed all antimicrobial therapy within 14 days of therapy initiation.
  • Patients may not have evidence of uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure (New York Heart Association (NYHA) class III or higher, unstable angina, or myocardial infarction within the past 6 months. Patients with a history of any significant cardiovascular disease that has been controlled for at least 14 days before registration are allowed (except for patients who have had a myocardial infarction within 6 months).
  • No systemic treatment, within 14 days before the first dose of ibrutinib with moderate or strong inhibitors of CYP3A (Strong Inhibitors: ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, and telithromycin; Moderate Inhibitors: fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitant, amprenavir, fosamprenavir, crizotinib, imatinib, verapamil, ciprofloxacin, grapefruit juice products, and Seville oranges) or strong CYP3A inducers for ibrutinib and ixazomib (carbamazepine, rifampin, phenytoin, St. John's wort).
  • Patients with ongoing or active systemic infection, active hepatitis B or C virus infection, or known Human Immunodeficiency Virus (HIV) positive are not eligible. Testing is not required in absence of clinical suspicion.
  • Patients with a history of hepatitis B or C must have a negative peripheral blood Polymerase Chain Reaction (PCR) and may not be positive for Hepatitis B surface antigen. Patients with cirrhosis or other evidence of liver damage due to Hepatitis B or C are not eligible.
  • Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of the treatment according to the protocol are not eligible.
  • Patients with a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible.
  • Patients with known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ibrutinib including difficulty swallowing are not eligible.
  • Patients with ≥ Grade 2 peripheral neuropathy, or Grade 1 peripheral neuropathy with pain on clinical examination during the screening period are not eligible.
  • Patients may not participate in any other therapeutic clinical trials, including those with other investigational agents not included in this trial throughout the duration of this study.
  • As ibrutinib will not be provided by the study, the patient must be able to obtain ibrutinib through other means (i.e., commercially or through patient assistance programs). This must be confirmed prior to registration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03323151


Contacts
Contact: Carolyn Andrews, RN 267-207-4070 candrews@precogllc.org

Locations
United States, Georgia
Winship Cancer Institute of Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Vanessa Smith    404-778-2214    vanessa.smith@emory.edu   
Contact: Terra Burney    404-712-0465    terra.l.burney@emory.edu   
Principal Investigator: Jonathon Cohen, MD         
United States, New Jersey
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Oniel Padilla Escalera, MPH    732-235-5972    op100@cinj.rutgers.edu   
Contact: Dama Bhavsar    732-235-6008    bhavsadm@cinj.rutgers.edu   
Principal Investigator: Kevin David, MD         
United States, New York
Laura and Isaac Perlmutter Cancer Center at NYU Recruiting
New York, New York, United States, 10016
Contact: Angela Tan    646-501-7869    angela.tan@nyumc.org   
Contact: Nancy Doan    646-501-7921    nancy.doan@nyumc.org   
Principal Investigator: Catherine Diefenbach, MD         
United States, Pennsylvania
University of Pennsylvania Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Joseph Vena    215-584-3073    joseph.vena@uphs.upenn.edu   
Contact: Shannon Cosgrove    215-220-9632    shannon.cosgrove@uphs.upenn.edu   
Principal Investigator: Daniel Landsburg, MD         
Reading Hospital/McGlinn Cancer Institute Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Barbara Miller, RN    484-628-8549    barbara.miller@towerhealth.org   
Contact: Janet Knoblauch, RN    484-628-9376    janet.knoblauch@towerhealth.org   
Principal Investigator: Terrence Cescon, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Erica Stallard    434-243-2649    Elg9r@hscmail.mcc.vriginia.edu   
Contact: Kimberly Underwood    434-982-3947    Km3q@hscmail.mcc.virginia.edu   
Principal Investigator: Craig Portell, MD         
United States, West Virginia
West Virginia University Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Sylvia McEwuen    304-293-1683    smcewuen@hsc.wvu.edu   
Contact: Valerie Phillips    304-581-1880    vphillip@hsc.wvu.edu   
Principal Investigator: Abraham Kanate, MD         
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Contact: Kaitlin Chambers    608-263-5006    kchambers2@wisc.edu   
Contact: Craig Augustine    608-265-5542    cfaugustine@wisc.edu   
Principal Investigator: Christopher Fletcher, MD         
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Katelyn Gauger    414-805-4587    kgauger@mcw.edu   
Contact: Kristin Mikulice    414-805-4627    kmikulice@mcw.edu   
Principal Investigator: Mehdi Hamadani, MD         
ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Chanda Miller    262-928-5539    chanda.miller@phci.org   
Contact: Amelia Crouse    262-928-2143    amelia.crouse@phci.org   
Principal Investigator: Timothy Wassenaar, MD         
Sponsors and Collaborators
PrECOG, LLC.
Takeda
Investigators
Study Chair: Jonathon B Cohen, MD Emory University - Winship Cancer Institute

Publications:

Responsible Party: PrECOG, LLC.
ClinicalTrials.gov Identifier: NCT03323151     History of Changes
Other Study ID Numbers: PrE0404
X16077 ( Other Identifier: Takeda )
First Posted: October 26, 2017    Key Record Dates
Last Update Posted: November 2, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data is proprietary.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by PrECOG, LLC.:
Relapsed Mantle-Cell Lymphoma
Refractory Mantle-Cell Lymphoma
Ixazomib
Ibrutinib
Proteasome Inhibitor
Bruton's Tyrosine Kinase Inhibitor

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Ixazomib
Glycine
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Glycine Agents
Neurotransmitter Agents
Physiological Effects of Drugs